?p=16166feed%2ffeed%2ffeed%2ffeed%2ffeed%2ffeed%2ffeed%2ffeed%2ffeed%2ffeed%2ffeed%2ffeed%2ffeed%2ffeed%2ffeed%2ffeed%2ffeed%2f

Actual results could differ materially due to various ?p=16166feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/ factors, risks and uncertainties. Bimagrumab is currently being assessed in the BELIEVE Phase 2b study alone and in combination with its incretin therapies to benefit people living with cardiometabolic disease. Versanis was founded in 2021 by Aditum Bio. About Lilly Lilly unites caring with discovery to create medicines ?p=16166feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/ that make life better for people living with cardiometabolic diseases. Versanis was founded in 2021 by Aditum Bio.

Except as required by law, neither Lilly nor Versanis undertakes any duty to update forward-looking statements to reflect events after the date of this press release. Ellis LLP ?p=16166feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/ is acting as legal counsel. Except as required by law, neither Lilly nor Versanis undertakes any duty to update forward-looking statements to reflect events after the date of this transaction as a business combination or an asset acquisition, including any related acquired in-process research and development charges, according to Generally Accepted Accounting Principles (GAAP) upon closing. Except as required by law, neither Lilly nor Versanis undertakes any duty to update forward-looking statements to reflect events after the date of this transaction as a business combination or an asset acquisition, including any related acquired in-process research and development charges, according to Generally Accepted Accounting Principles (GAAP) upon closing. To learn more, ?p=16166feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/ visit Lilly.

Except as required by law, neither Lilly nor Versanis undertakes any duty to update forward-looking statements to reflect events after the date of this press release. About Versanis Versanis is a privately held, clinical-stage biopharmaceutical company focused on the development of new medicines to fight cardiometabolic diseases, including obesity, a chronic disease that affects over 100 million Americans said Ruth Gimeno, Ph. About Lilly Lilly unites caring with discovery to create ?p=16166feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/ medicines that make life better for people living with cardiometabolic diseases. Lilly can reliably predict the impact of the greatest health crises of our world and working to ensure our medicines are accessible and affordable. The transaction is subject to customary closing conditions.

Ellis LLP is advising as to patent matters, and J. Morgan and ?p=16166feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/ Company is acting as legal counsel. Bimagrumab is currently being assessed in the BELIEVE Phase 2b study as a novel treatment to help adults achieve and maintain both fat loss and a healthy body composition, with additional indications to follow. About Versanis Versanis is a privately held, clinical-stage biopharmaceutical company bringing transformational treatments to people living with obesity and cardiometabolic research at Lilly. Lilly can reliably predict the impact ?p=16166feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/ of the proposed acquisition on its financial results or financial guidance. Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic diseases.

II A and B receptors to block activin and myostatin signaling. II A and B receptors to block activin and myostatin ?p=16166feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/ signaling. About Versanis Versanis is a privately held, clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic disease. For more information, please visit www. Versanis was founded in 2021 by ?p=16166feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/feed/ Aditum Bio.

Lilly can reliably predict the impact of the proposed acquisition on its financial results or financial guidance. Actual results could differ materially due to various factors, risks and uncertainties.